# NurOwn (debamestrocel) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/debamestrocel

> NurOwn (debamestrocel), sponsored by BRAINSTORM CELL THERAPEUTICS INC. (BCLI): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | NurOwn (debamestrocel) |
| Codes |  |
| Sponsor | BRAINSTORM CELL THERAPEUTICS INC. (BCLI) https://sec-api.dev/companies/bcli/catalysts |
| Indications | mild to moderate als |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### March 24, 2021: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001410578-24-002000): "On March 24, 2021, we announced positive top-line data from our Phase 2 trial evaluating three repeated intrathecal administrations of NurOwn®, each given 2 months apart, as a treatment for PMS." https://www.sec.gov/Archives/edgar/data/1137883/000141057824002000/bcli-20240930x10q.htm
- SEC Form 10-Q (accession 0001410578-24-002000): "On March 24, 2021, the Company announced positive top-line data in the Phase 2 study evaluating three repeated administrations of NurOwn®, each given 2 months apart, as a treatment for PMS." https://www.sec.gov/Archives/edgar/data/1137883/000141057824002000/bcli-20240930x10q.htm

### September 9, 2022: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2025-11-14.
- SEC Form 10-Q (accession 0001104659-25-112701): "On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS." https://www.sec.gov/Archives/edgar/data/1137883/000110465925112701/bcli-20250930x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001782): "On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057825001782/bcli-20250630x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001347): "On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057825001347/bcli-20250331x10q.htm
- SEC Form 10-K (accession 0001410578-25-000545): "On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057825000545/bcli-20241231x10k.htm
- SEC Form 10-Q (accession 0001410578-24-002000): "On September 9, 2022, we filed a BLA to the FDA for NurOwn® for the treatment of ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057824002000/bcli-20240930x10q.htm

### September 22, 2023: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: mild to moderate ALS.
- First seen 2024-11-14, last confirmed 2026-08-14.
- SEC Form 10-Q (accession 0001104659-26-097275): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000110465926097275/bcli-20260630x10q.htm
- SEC registration statement (S-1) (accession 0001104659-26-064628): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000110465926064628/bcli-20260331xs1.htm
- SEC Form 10-Q (accession 0001104659-26-062648): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000110465926062648/bcli-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-037927): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000110465926037927/bcli-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-112701): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000110465925112701/bcli-20250930x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001782): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057825001782/bcli-20250630x10q.htm
- SEC Form 10-Q (accession 0001410578-25-001347): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057825001347/bcli-20250331x10q.htm
- SEC Form 10-K (accession 0001410578-25-000545): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057825000545/bcli-20241231x10k.htm
- SEC Form 10-Q (accession 0001410578-24-002000): "On September 22, 2023, we submitted an amendment to our BLA to revise the indication to NurOwn® for the treatment of mild to moderate ALS." https://www.sec.gov/Archives/edgar/data/1137883/000141057824002000/bcli-20240930x10q.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-03-31, last confirmed 2026-05-21.
- SEC registration statement (S-1) (accession 0001104659-26-064628): "In 2026 and the upcoming years, the Company will focus on initiating and completing a Phase 3b trial and commercialization of NurOwn® for ALS, if approved." https://www.sec.gov/Archives/edgar/data/1137883/000110465926064628/bcli-20260331xs1.htm
- SEC Form 10-K (accession 0001104659-26-037927): "In 2026 and the upcoming years, the Company will focus on initiating and completing a Phase 3b trial and commercialization of NurOwn® for ALS, if approved." https://www.sec.gov/Archives/edgar/data/1137883/000110465926037927/bcli-20251231x10k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/debamestrocel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NurOwn (debamestrocel) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/debamestrocel

```bibtex
@misc{secapidev_pdufa_debamestrocel_20261116,
  title        = {NurOwn (debamestrocel) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/debamestrocel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_debamestrocel_20261116","title":"NurOwn (debamestrocel) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/debamestrocel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
